Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Placenta ; 35(1): 44-9, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24280234

ABSTRACT

INTRODUCTION: Intrauterine Growth Restriction (IUGR) is a multifactorial disease defined by an inability of the fetus to reach its growth potential. IUGR not only increases the risk of neonatal mortality/morbidity, but also the risk of metabolic syndrome during adulthood. Certain placental proteins have been shown to be implicated in IUGR development, such as proteins from the GH/IGF axis and angiogenesis/apoptosis processes. METHODS: Twelve patients with term IUGR pregnancy (birth weight < 10th percentile) and 12 CTRLs were included. mRNA was extracted from the fetal part of the placenta and submitted to a subtraction method (Clontech PCR-Select cDNA Subtraction). RESULTS: One candidate gene identified was the long non-coding RNA NEAT1 (nuclear paraspeckle assembly transcript 1). NEAT1 is the core component of a subnuclear structure called paraspeckle. This structure is responsible for the retention of hyperedited mRNAs in the nucleus. Overall, NEAT1 mRNA expression was 4.14 (±1.16)-fold increased in IUGR vs. CTRL placentas (P = 0.009). NEAT1 was exclusively localized in the nuclei of the villous trophoblasts and was expressed in more nuclei and with greater intensity in IUGR placentas than in CTRLs. PSPC1, one of the three main proteins of the paraspeckle, co-localized with NEAT1 in the villous trophoblasts. The expression of NEAT1_2 mRNA, the long isoform of NEAT1, was only modestly increased in IUGR vs. CTRL placentas. DISCUSSION/CONCLUSION: The increase in NEAT1 and its co-localization with PSPC1 suggests an increase in paraspeckles in IUGR villous trophoblasts. This could lead to an increased retention of important mRNAs in villous trophoblasts nuclei. Given that the villous trophoblasts are crucial for the barrier function of the placenta, this could in part explain placental dysfunction in idiopathic IUGR fetuses.


Subject(s)
Fetal Growth Retardation/physiopathology , Placenta/physiopathology , RNA, Long Noncoding/metabolism , Trophoblasts/metabolism , Adult , Cell Nucleus/metabolism , Female , Humans , Pregnancy
2.
J Reprod Immunol ; 94(2): 175-82, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22436290

ABSTRACT

Successful implantation is still the limiting step in IVF. We hypothesized that maternal plasma concentrations of certain cytokines at the time of embryo transfer could predict the likelihood of successful implantation and pregnancy. sIL-2R, IL-6, LIF, and MMP2 concentrations were measured in plasma from 160 IVF patients (natural and stimulated IVF cycles) on the morning of the embryo transfer (ET0) and 14 days later (ET+14). Patients were ultimately subdivided into four groups depending on the IVF treatment outcome (pregnancy failure, biochemical pregnancy, first-trimester miscarriage and normal term delivery). In natural and stimulated IVF cycles at ET0, sIL-2R concentrations were threefold higher in biochemical pregnancies than in pregnancy failures (P=0.020), and in natural cycles only, 2.5-fold higher in normal term deliveries than in pregnancy failures (P=0.023). Conversely, in natural and stimulated IVF cycles at ET0, LIF concentrations were one third lower in biochemical pregnancies/first-trimester miscarriages compared with pregnancy failures (P=0.042). We suggest that high sIL-2R and low LIF concentrations in maternal plasma on the morning of the embryo transfer might be associated with increased risks of early pregnancy loss, while a basal level of sIL-2R is necessary for normal term delivery outcome. Both cytokine measurements might therefore be useful in the management of IVF patients, and modulation of their concentrations could be investigated as a therapeutic alternative for women with abnormal concentrations at the time of embryo transfer.


Subject(s)
Fertilization in Vitro , Infertility/diagnosis , Infertility/therapy , Leukemia Inhibitory Factor/blood , Receptors, Interleukin-2/blood , Adult , Biomarkers/blood , Embryo Transfer , Female , Follow-Up Studies , Humans , Infertility/immunology , Matrix Metalloproteinase 2/blood , Predictive Value of Tests , Prognosis , Prospective Studies , Treatment Outcome
3.
Gynecol Obstet Invest ; 70(4): 299-305, 2010.
Article in English | MEDLINE | ID: mdl-21051851

ABSTRACT

INTRODUCTION: Small for gestational age (SGA) is an important problem affecting 10% of pregnancies and is associated with significant perinatal morbidity. In about 80% of cases, a probable etiology or a major risk factor can be identified. But almost 20% of SGA cases are considered unexplained. The 60-kDa heat shock protein (HSP60) is a highly immunogenic protein whose synthesis is greatly upregulated under nonphysiological conditions. Bacterial and human HSP60 share a high degree of sequence homology, and immunity to conserved epitopes may result in development of autoimmunity following a bacterial infection. We hypothesized that unexplained SGA could be the consequence of immune sensitization to human HSP60. METHODS: Unexplained SGA fetuses were identified by ultrasound biometry with normal Doppler velocimetry and with no detectable maternal or fetal abnormalities. Fetal sera were obtained by cordocentesis performed for a karyotype analysis in cases of unexplained SGA (study group) or for screening of Rhesus incompatibility (control group). Fetal sera were tested for HSP60 antigen and for IgG and IgM anti-HSP60 by ELISA as well as for other immune and hematological parameters. RESULTS: Maternal parameters were similar between the 12 study cases and the 23 control cases. The mean gestational age at cordocentesis was 29 weeks. IgM anti-HSP60 was detected in 12 cases (100%) and in no controls (p < 0.00017), while IgG anti-HSP60 was detected in 7 cases (58%) and only 1 control (p < 0.001). Three of the 4 cases with the highest IgM antibody levels died. There were no differences in fetal serum levels of HSP60 antigen or other immune and hematological markers between the two groups. CONCLUSION: Fetuses with unexplained SGA are positive for IgM and IgG antibody to human HSP60 and the specific IgM antibody level is predictive of fetal mortality. Detection of these antibodies indicates that a placental perturbation and a fetal autoimmune reaction to HSP60 are associated with this developmental delay.


Subject(s)
Antibodies/blood , Chaperonin 60/immunology , Fetal Blood/immunology , Fetal Weight , Gestational Age , Adult , Biomarkers/blood , Chaperonin 60/blood , Cordocentesis , Female , Fetal Death/immunology , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Infant, Newborn , Infant, Small for Gestational Age/immunology , Karyotyping , Pregnancy , Ultrasonography, Prenatal
4.
Hum Reprod ; 23(5): 1200-6, 2008 May.
Article in English | MEDLINE | ID: mdl-18332090

ABSTRACT

BACKGROUND: Only 25% of IVF transfer cycles lead to a clinical pregnancy, calling for continued technical progress but also more in depth analysis of patients' individual characteristics. The interleukin-1 (IL-1) system and matrix metalloproteinases (MMPs) are strongly implicated in embryo implantation. The genes coding for IL-1Ra (gene symbol IL-1RN), IL-1beta, MMP2 and MMP9 bear functional polymorphisms. We analysed the maternal genetic profile at these polymorphic sites in IVF patients, to determine possible correlations with IVF outcome. METHODS: One hundred and sixty women undergoing an IVF cycle were enrolled and a buccal smear was obtained. The presence of IL-1RN variable number of tandem repeats and IL-1B + 3953, MMP2-1306 and MMP9-1562 single nucleotide substitutions were determined. Patients were divided into pregnancy failures (119), biochemical pregnancies (8) and clinical pregnancies (33). RESULTS: There was a 40% decrease in IL-1RN*2 allele frequency (P = 0.024) and a 45% decrease in IL-1RN*2 carrier status in the clinical pregnancy group as compared to the pregnancy failure group (P = 0.017). This decrease was still statistically significant after a multivariate logistic regression analysis. The likelihood of a clinical pregnancy was decreased accordingly in IL-1RN*2 carriers: odds ratio = 0.349, 95% confidence interval = 0.2-0.8, P = 0.017. The IL-1B, MMP2 and MMP9 polymorphisms showed no correlation with IVF outcome. CONCLUSIONS: IL-1RN*2 allele carriage is associated with a poor prognosis of achieving a pregnancy after IVF.


Subject(s)
Fertilization in Vitro , Interleukin 1 Receptor Antagonist Protein/genetics , Polymorphism, Genetic , Adult , Cohort Studies , Cryopreservation , Female , Gene Frequency , Humans , Logistic Models , Matrix Metalloproteinase 2/genetics , Matrix Metalloproteinase 9/genetics , Pregnancy , Pregnancy Outcome , Prospective Studies , Treatment Outcome
5.
Endocrinology ; 142(10): 4522-8, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11564718

ABSTRACT

GLP-1 (glucagon-like peptide-1) is a potent insulin secretagogue released from L cells in the intestine. The regulation of GLP-1 secretion has been described both in vivo and in vitro in several animal species, but data from human cellular models are lacking. For this purpose, factors and cell-signaling pathways regulating GLP-1 secretion were investigated in the NCI-H716 human intestinal cell line. After differentiation, these cells homogeneously produced 16.8 pmol GLP-1/mg protein with a basal release of 4.2% during a 2-h incubation period. Nutrients, such as palmitic acid, oleic acid, and meat hydrolysate, stimulated GLP-1 secretion in a dose-dependent manner, as did the cholinergic agonist carbachol and the neuromediator gastrin-releasing peptide. Along with stimulating GLP-1 release, gastrin-releasing peptide, like ionomycin, increased intracellular calcium levels. Activators of PKA and PKC were able to increase GLP-1 secretion in NCI-H716 cells. However, neither PKA activators nor meat hydrolysate increased proglucagon mRNA levels. These findings indicate that the NCI-H716 cell line constitutes a unique model to study the cellular mechanism of GLP-1 secretion in humans and suggest potential interspecies divergence in the regulation of proglucagon gene expression in enteroendocrine cells.


Subject(s)
Glucagon/metabolism , Intestines/physiology , Peptide Fragments/metabolism , Protein Precursors/metabolism , Animals , Cell Line , Diet , Dose-Response Relationship, Drug , Glucagon-Like Peptide 1 , Humans , Oleic Acid/pharmacology , Palmitic Acid/pharmacology , Protein Hydrolysates/pharmacology
6.
J Biol Chem ; 272(48): 30261-9, 1997 Nov 28.
Article in English | MEDLINE | ID: mdl-9374511

ABSTRACT

IDX-1 (islet/duodenum homeobox-1) is a transcription factor expressed in the duodenum and pancreatic beta and delta cells. It is required for embryonic development of the pancreas and transactivates the Glut2, glucokinase, insulin, and somatostatin genes. Here we show that exposure of isolated rat pancreatic islets to palmitic acid induced a approximately 70% decrease in IDX-1 mRNA and protein expression as well as 40 and 65% decreases in the binding activity of IDX-1 for its cognate cis-regulatory elements of the Glut2 and insulin promoters, respectively. The inhibitory effect of palmitic acid required its mitochondrial oxidation since it was prevented by the carnitine palmitoyltransferase I inhibitor bromopalmitic acid. The palmitic acid effect on IDX-1 was correlated with decreases in GLUT2 and glucokinase expression of 40 and 25%, respectively, at both the mRNA and protein levels. Insulin and somatostatin mRNA expression was also decreased by 40 and 60%, whereas glucagon mRNA expression was not modified. After 48 h of exposure to fatty acids, total islet insulin, somatostatin, and glucagon contents were decreased by 85, 55, and 65%, respectively. At the same time, total hormone release was strongly stimulated (13-fold) for glucagon, whereas its was only marginally increased for insulin and somatostatin (1.5- and 1.7-fold, respectively). These results indicate that elevated fatty acid levels 1) negatively regulate Idx-1 expression; 2) decrease the expression of genes transactivated by IDX-1 such as those for GLUT2, glucokinase, insulin, and somatostatin; and 3) lead to an important increase in glucagon synthesis and secretion. Fatty acids thus have pleiotropic effects on pancreatic islet gene expression, and the negative control of Idx-1 expression may be an initial event in the development of these multiple defects.


Subject(s)
Fatty Acids/physiology , Glucokinase/metabolism , Homeodomain Proteins , Insulin/metabolism , Islets of Langerhans/metabolism , Monosaccharide Transport Proteins/metabolism , Somatostatin/metabolism , Trans-Activators/metabolism , Animals , DNA-Binding Proteins/metabolism , Gene Expression Regulation , Glucagon/genetics , Glucagon/metabolism , Glucokinase/genetics , Glucose Transporter Type 2 , Insulin/genetics , RNA, Messenger/genetics , Rats , Rats, Sprague-Dawley , Sodium-Potassium-Exchanging ATPase/metabolism , Somatostatin/genetics , Trans-Activators/genetics
7.
J Biol Chem ; 272(6): 3216-22, 1997 Feb 07.
Article in English | MEDLINE | ID: mdl-9013557

ABSTRACT

GLUT2 expression is strongly decreased in glucose-unresponsive pancreatic beta cells of diabetic rodents. This decreased expression is due to circulating factors distinct from insulin or glucose. Here we evaluated the effect of palmitic acid and the synthetic glucocorticoid dexamethasone on GLUT2 expression by in vitro cultured rat pancreatic islets. Palmitic acid induced a 40% decrease in GLUT2 mRNA levels with, however, no consistent effect on protein expression. Dexamethasone, in contrast, had no effect on GLUT2 mRNA, but decreased GLUT2 protein by about 65%. The effect of dexamethasone was more pronounced at high glucose concentrations and was inhibited by the glucocorticoid antagonist RU-486. Biosynthetic labeling experiments revealed that GLUT2 translation rate was only minimally affected by dexamethasone, but that its half-life was decreased by 50%, indicating that glucocorticoids activated a posttranslational degradation mechanism. This degradation mechanism was not affecting all membrane proteins, since the alpha subunit of the Na+/K+-ATPase was unaffected. Glucose-induced insulin secretion was strongly decreased by treatment with palmitic acid and/or dexamethasone. The insulin content was decreased ( approximately 55 percent) in the presence of palmitic acid, but increased ( approximately 180%) in the presence of dexamethasone. We conclude that a combination of elevated fatty acids and glucocorticoids can induce two common features observed in diabetic beta cells, decreased GLUT2 expression, and loss of glucose-induced insulin secretion.


Subject(s)
Dexamethasone/pharmacology , Fatty Acids/pharmacology , Insulin/metabolism , Islets of Langerhans/metabolism , Monosaccharide Transport Proteins/metabolism , Animals , Glucose Transporter Type 2 , Insulin Secretion , Islets of Langerhans/drug effects , Male , Mifepristone/pharmacology , Palmitic Acid/pharmacology , Protein Processing, Post-Translational , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley
8.
Mol Cell Endocrinol ; 135(1): 59-65, 1997 Nov 30.
Article in English | MEDLINE | ID: mdl-9453241

ABSTRACT

GLUT2 expression is reduced in the pancreatic beta-cells of several diabetic animals. The transcriptional control of the gene in beta-cells involves at least two islet-specific DNA-binding proteins, GTIIa and PDX-1, which also transactivates the insulin, somatostatin and glucokinase genes. In this report, we assessed the DNA-binding activities of GTIIa and PDX-1 to their respective cis-elements of the GLUT2 promoter using nuclear extracts prepared from pancreatic islets of 12 week old db/db diabetic mice. We show that the decreased GLUT2 mRNA expression correlates with a decrease of the GTIIa DNA-binding activity, whereas the PDX-1 binding activity is increased. In these diabetic animals, insulin mRNA expression remains normal. The adjunction of dexamethasone to isolated pancreatic islets, a treatment previously shown to decrease PDX-1 expression in the insulin-secreting HIT-T15 cells, has no effect on the GTIIa and PDX-1 DNA-binding activities. These data suggest that the decreased activity of GTIIa, in contrast to PDX-1, may be a major initial step in the development of the beta-cell dysfunction in this model of diabetes.


Subject(s)
DNA/metabolism , Diabetes Mellitus/metabolism , Gene Expression , Homeodomain Proteins , Islets of Langerhans/metabolism , Monosaccharide Transport Proteins/genetics , Trans-Activators/metabolism , Animals , Glucose Transporter Type 2 , Insulin/genetics , Male , Mice , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley
9.
Diabetes ; 45(2): 257-61, 1996 Feb.
Article in English | MEDLINE | ID: mdl-8549871

ABSTRACT

Rat pancreatic alpha- and beta-cells are critically dependent on hormonal signals generating cyclic AMP (cAMP) as a synergistic messenger for nutrient-induced hormone release. Several peptides of the glucagon-secretin family have been proposed as physiological ligands for cAMP production in beta-cells, but their relative importance for islet function is still unknown. The present study shows expression at the RNA level in beta-cells of receptors for glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide I(7-36) amide (GLP-I), while RNA from islet alpha-cells hybridized only with GIP receptor cDNA. Western blots confirmed that GLP-I receptors were expressed in beta-cells and not in alpha-cells. Receptor activity, measured as cellular cAMP production after exposing islet beta-cells for 15 min to a range of peptide concentrations, was already detected using 10 pmol/l GLP-I and 50 pmol/l GIP but required 1 nmol/l glucagon. EC50 values of GLP-I- and GIP-induced cAMP formation were comparable (0.2 nmol/l) and 45-fold lower than the EC50 of glucagon (9 nmol/l). Maximal stimulation of cAMP production was comparable for the three peptides. In purified alpha-cells, 1 nmol/l GLP-I failed to increase cAMP levels, while 10 pmol/l to 10 nmol/l GIP exerted similar stimulatory effects as in beta-cells. In conclusion, these data show that stimulation of glucagon, GLP-I, and GIP receptors in rat beta-cells causes cAMP production required for insulin release, while adenylate cyclase in alpha-cells is positively regulated by GIP.


Subject(s)
Gastric Inhibitory Polypeptide/metabolism , Glucagon/metabolism , Peptide Fragments/metabolism , Protein Precursors/metabolism , Receptors, Gastrointestinal Hormone/metabolism , Receptors, Glucagon/metabolism , Receptors, Pancreatic Hormone/metabolism , Adenylyl Cyclases/metabolism , Animals , Cyclic AMP/metabolism , Gene Expression , Glucagon-Like Peptide 1 , Glucagon-Like Peptide-1 Receptor , Islets of Langerhans/metabolism , Male , RNA, Messenger/genetics , Rats , Rats, Wistar , Signal Transduction
11.
Diabetes ; 44(10): 1202-8, 1995 Oct.
Article in English | MEDLINE | ID: mdl-7556958

ABSTRACT

Glucose-dependent insulinotropic polypeptide (GIP) is a hormone secreted by the endocrine K-cells from the duodenum that stimulates glucose-induced insulin secretion. Here, we present the molecular characterization of the human pancreatic islet GIP receptor. cDNA clones for the GIP receptor were isolated from a human pancreatic islet cDNA library. They encoded two different forms of the receptor, which differed by a 27-amino acid insertion in the COOH-terminal cytoplasmic tail. The receptor protein sequence was 81% identical to that of the rat GIP receptor. When expressed in Chinese hamster lung fibroblasts, both forms of the receptor displayed high-affinity binding for GIP (180 and 600 pmol/l). GIP binding was displaced by < 20% by 1 mumol/l glucagon, glucagon-like peptide (GLP-I)(7-36) amide, vasoactive intestinal peptide, and secretin. However exendin-4 and exendin-(9-39) at 1 mumol/l displaced binding by approximately 70 and approximately 100% at 10 mumol/l. GIP binding to both forms of the receptor induced a dose-dependent increase in intracellular cAMP levels (EC50 values of 0.6-0.8 nmol/l) but no elevation of cytoplasmic calcium concentrations. Interestingly, both exendin-4 and exendin-(9-39) were antagonists of the receptor, inhibiting GIP-induced cAMP formation by up to 60% when present at a concentration of 10 mumol/l. Finally, the physical and genetic chromosomal localization of the receptor gene was determined to be on 19q13.3, close to the ApoC2 gene. These data will help study the physiology and pathophysiology of the human GIP receptor.


Subject(s)
Chromosomes, Human, Pair 19 , Islets of Langerhans/metabolism , Polymorphism, Restriction Fragment Length , Receptors, Gastrointestinal Hormone/biosynthesis , Receptors, Gastrointestinal Hormone/genetics , Amino Acid Sequence , Animals , Apolipoprotein C-II , Apolipoproteins C/genetics , Calcium/metabolism , Chromosome Mapping , Cloning, Molecular , Cyclic AMP/metabolism , Deoxyribonucleases, Type II Site-Specific , Gastric Inhibitory Polypeptide/metabolism , Gene Expression , Gene Library , Genetic Linkage , Glucose/pharmacology , Humans , In Situ Hybridization, Fluorescence , Kinetics , Molecular Sequence Data , Rats , Receptors, Gastrointestinal Hormone/drug effects , Restriction Mapping , Sequence Homology, Amino Acid
SELECTION OF CITATIONS
SEARCH DETAIL
...